Drugs / Lm-GUCY2C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07417488 | Apr 2026 → Oct 2027 expected | colorectal cancer, small intestine adenocarcinoma | Thomas Jefferson University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lm-GUCY2C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07417488 ↗ |
| Modality | Vaccine | “Lm-GUCY2C vaccine administered as an intravenous infusion at dose levels 1 x 10⁸, 3 x 10⁸, 1 x 10⁹, and 3 x 10⁹ colony-forming units (CFU) as booster vaccinations given twice...” NCT07417488 ↗ |
| Route | Intravenous | “Lm-GUCY2C vaccine administered as an intravenous infusion” NCT07417488 ↗ |